[ CAS No. 5308-28-1 ]

Name: 5308-28-1|1-Isobutylpiperazine|98%
Brand: Ambeed
SKU: A681007
Price: 27.0 USD
Availability: InStock
Rating: 98 (40 reviews)

{[proInfo.proName]} ,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

DV 2D 3D

Structure of 5308-28-1 * Storage: {[proInfo.prStorage]}

Cart0 Bulk Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 88K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 5308-28-1 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 5308-28-1 ]

SDS

Alternatived Products of [ 5308-28-1 ]

Product Details of [ 5308-28-1 ]

CAS No. :	5308-28-1	MDL No. :	MFCD00190596
Formula :	C₈H₁₈N₂	Boiling Point :	184.9°C at 760 mmHg
Linear Structure Formula :	-	InChI Key :	N/A
M.W :	142.24 g/mol	Pubchem ID :	-
Synonyms :

Safety of [ 5308-28-1 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P261-P301+P312-P302+P352-P304+P340-P305+P351+P338	UN#:	N/A
Hazard Statements:	H302-H315-H319-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 5308-28-1 ]

Downstream synthetic route of [ 5308-28-1 ]

[ 5308-28-1 ] Synthesis Path-Downstream 1~16

1
[ 5308-28-1 ]
[ 22117-85-7 ]
[ 102535-28-4 ]

Reference： [1]Journal of Medicinal Chemistry,1986,vol. 29,p. 1814 - 1820

2
[ 5308-28-1 ]
[ 102359-00-2 ]
[ 102358-81-6 ]

Reference： [1]Chemical and Pharmaceutical Bulletin,1988,vol. 36,p. 2253 - 2258

3
[ 5308-28-1 ]
[ 93107-30-3 ]
1-Cyclopropyl-6-fluoro-7-(4-isobutyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,1996,vol. 39,p. 729 - 735

4
[ 629625-93-0 ]
[ 5308-28-1 ]

Yield	Reaction Conditions	Operation in experiment
86.2%	With palladium 10% on activated carbon; hydrogen at 20℃; for 20h;	1-Cyclohexylpyrrolidin-3-amine I-6 General procedure: To a solution of compound I-5 (240 mg) in HFIP (8 mL), 10% Pd/C (120 mg) was added and thenthe reaction mixture was stirred under H2 at room temperature and 1atm for 20 h. Then themixture was filtrated and the filtrate was concentrated to give compound I-6 as yellow oil (100 mg,75%).
	With hydrogen In ethanol at 20℃; for 12h;	2 Benzyl 1-piperazinecarboxylate (1.1 g, 5.00 mmol) and isobutylaldehyde (0.91 mL, 10.0 mmol) were dissolved in 30 mL of tetrahydrofuran, and acetic acid (0.57 mL, 10.0 mmol) and sodium triacetoxyborohydride (2.11 g, 10.0 mmol) were added thereto, and the reaction mixture was stirred at room temperature for two hours. The reaction mixture was mixed with a 1N aqueous solution of sodium hydroxide, extracted with ethyl acetate twice, and the combined organic layers were washed with brine once. The mixture was dried over anhydrous sodium sulfate and evaporated. The resulting residue was purified by silica gel column chromatography (Fuji Silysia, NH Silica gel; ethyl acetate:hexane=50:50) to give benzyl 4-isobutylpiperazin-1-carboxylate (1.05 g) as a colorless oil. The resulting benzyl 4-isobutylpiperazin-1-carboxylate (1.05 g) was dissolved in 35 mL of ethanol, 10% palladium-carbon (750 mg) was added thereto, and the reaction mixture was stirred at room temperature under hydrogen atmosphere (1 atm) for 12 hours. The palladium-carbon was removed by filtration, and the filtrate was evaporated to give the title compound (610 mg) as a colorless oil.1H-NMR Spectrum (CDCl3,400MHz) δ(ppm): 0.90(6H,d,J=6.8Hz), 1.71-1.86(1H,m),2.07(2H,d,J=7.6Hz),2.33-2.43(4H,m),2.86-2.93(4H,m).

Reference： [1]Zhou, Jie; Ji, Ming; Zhu, Zhixiang; Cao, Ran; Chen, Xiaoguang; Xu, Bailing [European Journal of Medicinal Chemistry, 2017, vol. 132, p. 26 - 41]
[2]Current Patent Assignee: EISAI CO LTD - EP1508570, 2005, A1 Location in patent: Page/Page column 134-135

5
1-(isobutyl)-4-(4-nitrophenylpiperazine) [ No CAS ]
1-(isobutyl)-4-(4-nitrophenyl)piperazine [ No CAS ]
[ 5308-28-1 ]
4-[4-(isobutyl)-1-piperazinyl]benzenamine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
94%	In ethanol	14.E.B B. B. 4-[4-(isobutyl)-1-piperazinyl]benzenamine A mixture of 1-(isobutyl)-4-(4-nitrophenylpiperazine) (9.4 g, 35.7 mmol) (from Step A above) and 10% palladium-on-charcoal in ethanol (175 mL) was hydrogenated at room temperature at 20 psi for 1.25 hour. The catalyst was filtered off and the filter cake washed thoroughly with ethanol. The mixture was evaporated under reduced pressure to give 4-[4-(isobutyl)-1-piperazinyl] benzenamine (7.8 g, 94%) as a dark red solid.

Reference： [1]Current Patent Assignee: ROCHE HOLDING AG - US2002/151554, 2002, A1

6
[ 5308-28-1 ]
[ 84468-15-5 ]
1-(5-isoquinolinesulfonyl)-4-isobutylpiperazine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
78%	With sodium hydroxide; potassium carbonate In chloroform methanol; chloroform	9 EXAMPLE 9 EXAMPLE 9 In 30 ml of chloroform were added 1.42 g of 1-isobutylpiperazine and 2.76 g of potassium carbonate, and to the mixture was added dropwise 50 ml of a chloroform solution containing 2.28 g of 5-isoquinolinesulfonyl chloride under cooling with ice. After the dropwise addition of the chloroform solution, the mixed solution thus obtained was stirred at a temperature of 15° C. to 25° C. for two hours, and then the reaction solution was washed with 20 ml of a 1N aqueous sodium hydroxide solution and extracted twice with a 5N aqueous hydrochloric acid solution. The aqueous hydrochloric acid layer was rendered alkaline, extracted three time with 30 ml of chloroform, and the chloroform layer extracted was washed with water and dried with anhydrous magnesium sulfate. After the chloroform was distilled therefrom under reduced pressure, the residue obtained was subjected to a silica gel column chromatography (silica gel: 100 g; solvent: 2% methanol-chloroform) to give 2.60 g of 1-(5-isoquinolinesulfonyl)-4-isobutylpiperazine, i.e., Compound (47) in a yield of 78%. Melting point (the dihydrochloride recrystallized from ethanol): 234° C. Mass spectrum (m/e): 333(M+), 290(M-C3 H7), 141 and 128 NMR spectrum (CDCl3, δ): 0.8(6H, d, 2CH3), 1.2-2.0(1H, m, CH), 2.0-3.3(10H, 5NCH2), 7.6-8.8(5H) and 9.3(1H, s) IR absorption spectrum (νmax,cap cm-1): 3430, 1620, 1350, 1340, 1170 and 1145.

Reference： [1]Current Patent Assignee: HIDAKA; ASAHI KASEI CORPORATION - US4456757, 1984, A

7
[ 5308-28-1 ]
[ 662116-67-8 ]
[ 942948-54-1 ]

Yield	Reaction Conditions	Operation in experiment
60%	With N-ethyl-N,N-diisopropylamine In isopropyl alcohol at 45℃; for 18h;	36 5-Chloro-4-(4-isobutylpiperazin-1-yl)-3-nitropyridin-2-amine To a mixture of 2-amino-4,5-dichloro-3-nitropyridine (0.060 g, 0.29 mmol) and isopropanol (4.5 ml) was added 1-isobutyl-piperazine (0.045 g, 0.32 mmol) with the aid of isopropanol (0.5 ml) followed by diisopropylethylamine (0.06 ml, 0.32 mmol). The reaction mixture was heated at 45° C. for 18 h, then allowed to cool to room temperature, and concentrated in vacuo. The residue was absorbed on silica gel, the free running powder was placed on a 10 g isolute silica column which was eluted with ethyl acetate/dichloromethane (v/v; 1:1). The title compound was obtained as an orange solid (0.054 g, 60%); 1H-NMR (500 MHz, DMSO-d6) 0.87 (d, J=6.57 Hz, 6H, CH(CH3)2), 1.77 (m, 1H, CH(CH3)2), 2.08 (d, J=7.39 Hz, 2H, N-CH2), 2.45 (br s, 4H, piperazine N(CH2)2), 3.05 (br s, 4H, piperazine N(CH2)2), 6.94 (s, 2H, NH2), 8.06 (s, 1H, 6-H);LC (Method B)-MS (ESI, m/z): Rt=1.70 min-314, 316 [(M+H)+, Cl isotopic pattern].

Reference： [1]Current Patent Assignee: UNIVERSITY OF LONDON - US2009/247507, 2009, A1 Location in patent: Page/Page column 27

8
[ 5308-28-1 ]
[ 942947-95-7 ]
[ 942948-47-2 ]

Yield	Reaction Conditions	Operation in experiment
63%	With N-ethyl-N,N-diisopropylamine; In isopropyl alcohol; at 45℃; for 20h;	To a mixture of <strong>[942947-95-7]5-bromo-4-chloro-3-nitro-pyridin-2-ylamine</strong> (0.126 g, 0.50 mmol) and isopropanol (9 ml) was added 1-isobutylpiperazine (0.078 g, 0.55 mmol) with the aid of isopropanol (5 ml) followed by diisopropylethylamine (0.10 ml, 0.57 mmol). The reaction mixture was heated at 45 C. for 20 h, then allowed to cool to room temperature. The precipitate was collected by filtration and washed with isopropanol and diethyl ether. The title compound was thus obtained as a yellow solid (0.112 g, 63%). 1H-NMR (500 MHz, DMSO-d6) 0.87 (d, J=6.56 Hz, 6H, CH(CH3)2), 1.77 (m, 1H, CH(CH3)2), 2.08 (d, J=7.35 Hz, 2H, N-CH2), 2.47 (br s, 4H, piperazine N(CH2)2), 3.04 (br s, 4H, piperazine N(CH2)2), 6.96 (s, 2H, NH2), 8.15 (s, 1H, 6-H);LC (Method B)-MS (ESI, m/z): Rt=1.80 min-358, 360 [(M+H)+, Br isotopic pattern].

Reference： [1]Patent: US2009/247507,2009,A1 .Location in patent: Page/Page column 25
[2]Journal of Medicinal Chemistry,2010,vol. 53,p. 5213 - 5228

9
[ 5308-28-1 ]
[ 27514-08-5 ]
[ 1214265-89-0 ]

Yield	Reaction Conditions	Operation in experiment
54%		Preparation 16: 4-(4-i-Butylpiperazin-l-yl)cyclohexanamine (cis and trans isomers); [0126] In a 250 mL flask, <strong>[27514-08-5]4-acetamidocyclohexanone</strong> (5.47 g, 35.2 mmol), N-i-butyl piperazine (10 g, 70.3 mmol) were dissolved in dry toluene (75 mL) and added methanesulfonic acid (MSA) (250 muL) and refluxed using Dean-Stark apparatus for five hours with occasional decanting toluene from Dean-Stark apparatus 3-4 times. Then removed half of the toluene from the apparatus and cooled to 500C and added 75 mL ethanol then removed the Dean-Stark apparatus and cooled to 15-200C. Added NaBH4 (35.2 mmol) portion wise under nitrogen atmosphere. Continued stirring the reaction for overnight. Then added NaBH4 (50 mmols), after 30 min added 12 rnL of 4 N HCl drop wise to the reaction. The volatiles were removed from the reaction under reduced pressure. Basified the gummy solid reaction mixture with 12 mL sat.K^CCh, diluted with another 12 mL water and further basified with 50% NaOH solution to pH about 13. Then added EtOAc (100 mL) and filtered the solid product and washed with EtOAc and ether and collected N-(4-(4-i-burtylpiperazin-l-yl)cyclohexyl)acetamide (cis and trans isomers) as white powder (5.3 g, 54%). ESI-MS: m/z 282 (M+H)+. N-(4-(4-propylpiperazin-l- yl)cyclohexyl)acetamide (5.2 g, 18.5 mmol) was refluxed in 24% cone. HCl solution for 20 hours at 115C. Then evaporated the solution under reduced pressure and the solid product obtained was dissolved and recrystallized from isopropyl alcohol to get the product as white hydrochloride salt (5.2 g). ESI-MS: m/z 240 (M+H) +.

Reference： [1]Patent: WO2010/25073,2010,A1 .Location in patent: Page/Page column 28-29

10
[ 5308-28-1 ]
[ 1245318-94-8 ]
[ 1245319-23-6 ]

Yield	Reaction Conditions	Operation in experiment
	With N-ethyl-N,N-diisopropylamine In 1,4-dioxane at 70℃; for 6h;	190 To a solution of 5-amino-7-chloro-2-(4-fluorophenyl)-oxazolo[5,4-d]pyrimidine X (50 mg, 0.19 mmol) in dioxane (5 ml) was added diisopropylethylamine (0.28 mmol, 47 μL) and a piperazine derivative (0.28 mmol). The reaction was stirred at 70° C. for 6 hours after which the solvent was removed in vacuo. The resulting residue was purified by flash chromatography on silica, the mobile phase being a mixture of methanol and dichloromethane (in a ratio gradually ranging from 100% CH2Cl2 to 2% CH3OH in CH2Cl2), yielding the pure title compounds which were characterized by their mass spectra as indicated below:The following compounds were synthesized according to this procedure:Example 190 Synthesis of 5-amino-2-(4-fluorophenyl)-7-(4-isobutylpiperazin-1-yl)-oxazolo[5,4-d]pyrimidineThis compound was obtained from 1-isobutyl-piperazine (32 mg);MS m/z (%): 371 ([M+H]+, 100).
32 mg	With N-ethyl-N,N-diisopropylamine In 1,4-dioxane at 70℃; for 6h;	190 Example 190 Synthesis of 5-amino-2-(4-fluorophenyl)-7-(4-isobutylpiperazin-1-yl)-oxazolo[5,4-d]pyrimidine Examples 190-192 Synthesis of 5-amino-2-(4-fluorophenyl)-7-piperazin-1-yl-oxazolo[5,4-d]pyrimidine analogues General Procedure [0979] To a solution of 5-amino-7-chloro-2-(4-fluorophenyl)-oxazolo[5,4-d]pyrimidine X (50 mg, 0.19 mmol) in dioxane (5 ml) was added diisopropylethylamine (0.28 mmol, 47 μL) and a piperazine derivative (0.28 mmol). The reaction was stirred at 70° C. for 6 hours after which the solvent was removed in vacuo. The resulting residue was purified by flash chromatography on silica, the mobile phase being a mixture of methanol and dichloromethane (in a ratio gradually ranging from 100% CH2Cl2 to 2% CH3OH in CH2Cl2), yielding the pure title compounds which were characterized by their mass spectra as indicated below: [0980] The following compounds were synthesized according to this procedure: Example 190 Synthesis of 5-amino-2-(4-fluorophenyl)-7-(4-isobutylpiperazin-1-yl)-oxazolo[5,4-d]pyrimidine This compound was obtained from 1-isobutyl-piperazine (32 mg); MS m/z (%): 371 ([M+H]+, 100).
32 mg	With N-ethyl-N,N-diisopropylamine In 1,4-dioxane at 70℃; for 6h;	190 Synthesis of 5-amino-2-(4-fluorophenyl)-7-(4-isobutylpiperazin-1-yl)-oxazolo[5,4-d]pyrimidine To a solution of 5-amino-7-chloro-2-(4-fluorophenyl)-oxazolo[5,4-d]pyrimidine X (50 mg, 0.19 mmol) in dioxane (5 ml) was added diisopropylethylamine (0.28 mmol, 47 μL) and a piperazine derivative (0.28 mmol). The reaction was stirred at 70° C. for 6 hours after which the solvent was removed in vacuo. The resulting residue was purified by flash chromatography on silica, the mobile phase being a mixture of methanol and dichloromethane (in a ratio gradually ranging from 100% CH2Cl2 to 2% CH3OH in CH2Cl2), yielding the pure title compounds which were characterized by their mass spectra as indicated below: [0996] The following compounds were synthesized according to this procedure: Example 190 Synthesis of 5-amino-2-(4-fluorophenyl)-7-(4-isobutylpiperazin-1-yl)-oxazolo[5,4-d]pyrimidine [0997] This compound was obtained from 1-isobutyl-piperazine (32 mg); [0998] MS m/z (%): 371 ([M+H]+, 100).

Reference： [1]Current Patent Assignee: KATHOLIEKE UNIVERSITEIT LEUVEN - US2012/46278, 2012, A1 Location in patent: Page/Page column 67
[2]Current Patent Assignee: KATHOLIEKE UNIVERSITEIT LEUVEN - US2013/190297, 2013, A1 Location in patent: Paragraph 0979; 0980; 0981; 0982
[3]Current Patent Assignee: KATHOLIEKE UNIVERSITEIT LEUVEN - US2014/88088, 2014, A1 Location in patent: Paragraph 0995-0998

11
[ 5308-28-1 ]
[ 1372616-37-9 ]
[ 1442655-83-5 ]

Yield	Reaction Conditions	Operation in experiment
74%	With manganese(IV) oxide In dimethyl sulfoxide at 20℃; for 24h;	RLZ analog (2e). A mixture of benzoxazinorifamycin 2d (5.5 mg, 0.005 mmol), l-(2- methylpropy piperazine (2.3 mg, 0.016 mmol; Oakwood Products Inc.), Mn02 (5 mg, 0.055 mmol) and DMSO (0.5 mL) was stirred at room temperature for 24 h and then filtered over Celite. The filtrate was concentrated and purified by preparative TLC, eluting with dichloromethane : methanol (90 : 10). The product band was processed to give 2e (4.6 mg, 74%) as a dark blue solid: HPLC 5.33 min (95.3% purity); MS (ES+) m/z 1189.5 (M+H)+; HRMS (MALDI) calcd for C49H61N3O13 [(M + H)+], 1189.6180; found 1189.6193.

Reference： [1]Current Patent Assignee: UNIVERSITY OF MICHIGAN - WO2013/86415, 2013, A1 Location in patent: Page/Page column 42

12
[ 5308-28-1 ]
[ 1610379-38-8 ]
[ 1610379-05-9 ]

Yield	Reaction Conditions	Operation in experiment
34%	With potassium carbonate In N,N-dimethyl-formamide at 110℃; for 6h;	5 2-(6-(4-Isobutylpiperazin-1-yl)pyridin-2-yl)-5,7-dimethoxyquinazolin-4(3H)-one Example 5 2-(6-(4-Isobutylpiperazin-1-yl)pyridin-2-yl)-5,7-dimethoxyquinazolin-4(3H)-one To a suspension of 2-(6-fluoropyridin-2-yl)-5,7-dimethoxyquinazolin-4(3H)-one (0.108 g, 0.36 mmol) in N,N-dimethylformamide (1.5 mL) was added K2CO3 (0.15 g, 1.07 mmol) and 1-isobutyl-piperazine (88.94, 0.54 mmol). The resulting mixture was heated at 110° C. for 6 h. After that time N,N-dimethylacetamide (1.5 mL) was added and heating was continued for 20 h. After that time the reaction mixture was cooled to rt, diluted with ethyl acetate and filtered. The filtrate was concentrated under reduced pressure and the residue was washed with water, and dried under high vacuum. The product was purified by flash column chromatography (silica gel, 99:1 dichloromethane/methanol) to give 2-(6-(4-isobutylpiperazin-1-yl)pyridin-2-yl)-5,7-dimethoxyquinazolin-4(3H)-one (0.052 g, 34%) as a yellow solid: mp 188-189° C.; 1H NMR (400 MHz, CDCl3) δ 10.33 (br s, 1H), 7.83 (d, J=7.42 Hz, 1H), 7.65 (dd, J=8.59, 7.42, 1H), 6.76-6.88 (m, 2H), 6.48 (d, J=2.34 Hz, 1H), 3.99 (s, 3H), 3.94 (s, 3H), 3.64 (t, J=4.88 Hz, 4H), 2.55 (t, J=4.88 Hz, 4H), 2.17 (d, J=7.42 Hz, 2H), 1.75-1.95 (m, 1H), 0.95 (d, J=6.64 Hz, 6H); ESI MS m/z 424 [M+H]+.

Reference： [1]Current Patent Assignee: ZENITH CAPITAL CORP - US2014/142102, 2014, A1 Location in patent: Paragraph 0522; 0523

13
[ 5308-28-1 ]
2-bromo-N-[1-(1H-indol-3-yl)hexan-2-yl]-1,3-thiazole-5-carboxamide [ No CAS ]
N-(1-(1H-indol-3-yl)hexan-2-yl)-2-(4-isobutylpiperazin-1-yl)thiazole-5-carboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
69%	With potassium carbonate In acetonitrile at 80℃; for 16h;	5 Example 5: N-(l-(lH-Indol-3-yl)hexan-2-yl)-2-(4-isobutylpiperazin-l-yl)thiazole-5- carboxamide. To a solution of N-(l-(lH-indol-3-yl)hexan-2-yl)-2-bromothiazole-5- carboxamide (0.20 g, 0.49 mmol) and 1-isobutylpiperazine (0.05 g, 0.54 mmol) in CH3CN (4.5 mL) was added K2C03 (0.20 g, 1.47 mmol) and the reaction mixture was heated at 80 °C for 16 h. The reaction mixture was concentrated in vacuo. The residue was diluted with H20 (10 mL) and extracted with 10% MeOH in DCM (10 mL). The organic layer was separated, dried over anhydrous Na2S04 and concentrated in vacuo. The crude obtained was purified by column chromatography (silica 230-400 mesh, 0 to 10% MeOH in DCM) and then triturating with petroleum ether (6 mL), pentane (10 mL) and DCM (2 mL) to afford N-(l-(lH-indol-3- yl)hexan-2-yl)-2-(4-isobutylpiperazin-l-yl)thiazole-5-carboxamide (0.16 g, 69%) as an off-white solid. HPLC Purity: 97.4%. LC/MS (ESI) m/e [M+H]+/RT (min)/%: 468.00/3.33/99.52%. 1H NMR (400 MHz, DMSO- 6) δ 0.81 (t, = 6.8 Hz, 3H), 0.87 (d, = 6.4 Hz, 6H), 1.13-1.37 (m, 4H), 1.42-1.58 (m, 2H), 1.76-1.82 (m, 1H), 2.08 (d, = 6.8 Hz, 2H), 2.40-2.48 (m, 4H), 2.73- 2.95 (m, 2H), 3.42-3.48 (m, 4H), 4.10-4.18 (m, 1H), 6.92-6.99 (m, 1H), 7.04 (t, J = 7.3 Hz, 1H), 7.09 (brs, 1H), 7.31 (d, / = 8.3 Hz, 1H), 7.57 (d, = 7.3 Hz, 1H), 7.80 (s, 1H), 7.94 (d, = 8.8 Hz, 1H), 10.75 (brs, 1H).

Reference： [1]Current Patent Assignee: UCB - WO2017/20010, 2017, A1 Location in patent: Paragraph 0115

14
[ 5308-28-1 ]
[ 779345-37-8 ]
[ 1374636-03-9 ]

Reference： [1]Journal of Medicinal Chemistry,2018,vol. 61,p. 9371 - 9385

15
[ 5308-28-1 ]
(2-(4-(trifluoromethyl) phenyl) acetyl)-L-tryptophan [ No CAS ]
(S)-N-(3-(1H-indol-3-yl)-1-(4-isobutylpiperazin-1-yl)-1-oxopropan-2-yl)-2-(4-(trifluoromethyl)phenyl)acetamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
77.6%	With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine In dichloromethane at 20℃;	General method for preparation of compounds 3a-3h,4a-4i, 5a-5k, and 6a-6d General procedure: Phenylacetic acid derivative (0.01 mol) or 3-(4-(trifluoromethyl)phenyl) propionic (0.01 mol) and L-tryptophanmethyl ester hydrochloride (0.01 mol) were added to anhydrousDCM; (100 mL), then Et3N (0.04 mol) was added, andthen the mixture was stirred for 10 min. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI)(0.012 mol) and 1-Hydroxybenzotriazole (HOBt)(0.7 mmol) were added and the mixture was stirred overnightat room temperature. Thereafter, the mixture waswashed with 0.1 N sodium hydroxide solution, 0.1 N HCl,and water. The organic layer was concentrated underreduced pressure to produce intermediates 1a-1i. Intermediate1 (5.0 mmol) was dissolved in methanol (20 mL) and heated to 60 oC. 1 N NaOH (10 mL) was added dropwiseand then stirred for 2 h at 60 oC. The reaction mixturewas cooled to room temperature, and the pH was adjusted to2-3 with HCl solution. The cake was filtered, washed withwater, and then dried under reduced pressure to obtainintermediates 2a-2i. Intermediate 2 (1.0 mmol) and variousamino derivatives (1.1 mmol) were added to anhydrousDCM (15 mL) and then Et3N (4.0 mmol), EDCI (1.2 mmol),and HOBt (0.07 mmol) were added. The mixture was stirredovernight at room temperature. Thereafter, the mixture waswashed with water, and then the crude product was crystallizedfrom methanol/water or purified by silica gel forcolumn chromatography (DCM/methanol) to obtain thetargeted product.

Reference： [1]Yu, Ming-jun; Li, Chao; He, Meng; Zhu, Yu-ting; Yang, Rui; Deng, Sheng-song; Meng, Xiao-ming; Yao, Ri-sheng [Medicinal Chemistry Research, 2021, vol. 30, # 11, p. 2069 - 2089]

16
[ 5308-28-1 ]
[ 64-18-6 ]
[ 160538-51-2 ]
3-[4-(2-methylpropyl)piperazin-1-yl]-4-nitrobenzaldehyde formate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
30%	Stage #1: 1-isobutylpiperazine With triethylamine; cesium fluoride In acetonitrile at 20℃; for 0.333333h; Stage #2: 3-fluoro-4-nitro-benzaldehyde In acetonitrile at 20℃; Stage #3: formic acid In water; acetonitrile	General procedure: General procedure 1 (13a-u). A solution of the corresponding amine (12a-u) (0.46 mmol, 1.3 Eq.), trimethylamine (1.06 mmol, 3 Eq.) and cesium fluoride (0.03 mmol, 0.1 Eq.) in ACN (1 ml) was stirred at room temperature for 20 min. To the reaction mixture was then added a solution of 3-fluoro-4-nitrobenzaldehyde (11) (0.35 mmol, 1 Eq.) in CAN (0.5 ml). The resulting reaction was then stirred at room temperature for 24 hours. After complete consumption of the starting materials - monitored by TLC (DCM/MeOH 19:1) and UHPLC-MS the mixture was filtered, and filtrate was evaporated under reduced pressure. Compound was purified by preparative HPLC. 3-(3-methoxyazetidin-1-yl)-4-nitrobenzaldehyde (13a). Compound 13a was synthesized using general procedure 1 and 3-azetidinyl methyl ether hydrochloride (12a). The crude reaction was purified using preparative HPLC to afford the desired compound as an orange amorphous solid (26 mg, 30% yield) with a purity of 98% by UHPLC-MS.
30%	Stage #1: 1-isobutylpiperazine With triethylamine; cesium fluoride In acetonitrile at 20℃; for 0.333333h; Stage #2: 3-fluoro-4-nitro-benzaldehyde In acetonitrile at 20℃; Stage #3: formic acid In water; acetonitrile	General procedure: General procedure 1 (13a-u). A solution of the corresponding amine (12a-u) (0.46 mmol, 1.3 Eq.), trimethylamine (1.06 mmol, 3 Eq.) and cesium fluoride (0.03 mmol, 0.1 Eq.) in ACN (1 ml) was stirred at room temperature for 20 min. To the reaction mixture was then added a solution of 3-fluoro-4-nitrobenzaldehyde (11) (0.35 mmol, 1 Eq.) in CAN (0.5 ml). The resulting reaction was then stirred at room temperature for 24 hours. After complete consumption of the starting materials - monitored by TLC (DCM/MeOH 19:1) and UHPLC-MS the mixture was filtered, and filtrate was evaporated under reduced pressure. Compound was purified by preparative HPLC. 3-(3-methoxyazetidin-1-yl)-4-nitrobenzaldehyde (13a). Compound 13a was synthesized using general procedure 1 and 3-azetidinyl methyl ether hydrochloride (12a). The crude reaction was purified using preparative HPLC to afford the desired compound as an orange amorphous solid (26 mg, 30% yield) with a purity of 98% by UHPLC-MS.

Reference： [1]Current Patent Assignee: EINDHOVEN UNIVERSITY OF TECHNOLOGY; TAROS CHEMICALS; UNIVERSITY OF CALIFORNIA - WO2021/203016, 2021, A2 Location in patent: Paragraph 0040; 1008; 1009-1010; 1020
[2]Current Patent Assignee: EINDHOVEN UNIVERSITY OF TECHNOLOGY; TAROS CHEMICALS; UNIVERSITY OF CALIFORNIA - WO2021/203016, 2021, A2 Location in patent: Paragraph 0040; 1008; 1009-1010; 1020

Related Products

Historical Records

Related Parent Nucleus of
[ 5308-28-1 ]

Piperazines

[ 57184-50-6 ]

1-(2,2-Dimethylpropyl)piperazine

Similarity: 1.00

[ 4649-58-5 ]

2-(4-Isobutylpiperazin-1-yl)ethanamine

Similarity: 1.00

[ 33174-08-2 ]

1-Isobutylpiperazine dihydrochloride

Similarity: 0.95

[ 510725-53-8 ]

1-Isobutylpiperazine hydrochloride

Similarity: 0.95

[ 879059-43-5 ]

2,2-Dimethyl-3-(4-methylpiperazin-1-yl)propan-1-amine

Similarity: 0.95

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 5308-28-1 ]

Quality Control of [ 5308-28-1 ]

Related Doc. of [ 5308-28-1 ]

Product Details of [ 5308-28-1 ]

Safety of [ 5308-28-1 ]

Application In Synthesis of [ 5308-28-1 ]

[ 5308-28-1 ] Synthesis Path-Downstream 1~16

Related Parent Nucleus of [ 5308-28-1 ]

Piperazines

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Related Parent Nucleus of
[ 5308-28-1 ]